Search

Resume. The search for new drugs with cytoprotective and anti-ischemic activity is an urgent task of modern pharmacology. These properties are necessary for the complex protection of renal parenchyma during organ preservation operations (renal resection), most often carried out in conditions of thermal ischemia. Only the combined use of modern highly effective drugs and the skill of an operating surgeon can prevent the development of acute renal injury (AKI) due to pinching of renal vessels. The aim of this study was to investigate the nephroprotective effects of a combination of a peptide mimicking the a-helix B of erythropoietin (pHBSP) and infliximab in ischemic reperfusion damage to the kidneys. Methods. The experiment was conducted on 50 white laboratory male Wistar rats weighing 280-320 g. Animals were injected with a peptide mimicking the a-helix B of erythropoietin (pHBSP) and infliximab. Under anesthesia, atraumatic vascular clamps were applied to the left renal pedicle for 40 minutes, nephrectomy on the right. Functional samples and laboratory tests were performed 5 minutes and 72 hours after reperfusion. Results. As a result of the study, it was shown that using a combination of the peptide simulating a-helix B erythropoietin (pHBSP) and infliximab in ischemic-reperfusion kidney injury showed significantly more pronounced nephroprotective effects than using the peptide mimicking a-helix B erythropoietin or infliximab in the mono mode. Conclusion.The results of the study show the promise of combined use of peptide simulating a-helix B erythropoietin (pHBSP) and infliximab in order to correct ischemic-reperfusion kidney injuries.

The search for drugs that can prevent the development of acute renal injury (ARI) is one of the main tasks of modern pharmacology. Methods.The experiment was carried out in 50 white Wistar male laboratory rats weighing 280-320 g. The animals were injected with a peptide mimicking the spatial structure of the B erythropoietin chain (pHBSP) and infliximab. Results.The combined use of a peptide mimicking the spatial structure of the B erythropoietin chain (pHBSP) and infliximab before renal ischemia-reperfusion injury is more effective than the nephroprotective properties of the above substances when it is selectively used. Conclusion. According to the results of the study, we can talk about the prospects of the combined use of the peptide mimicking the spatial structure of the B erythropoietin chain (pHBSP) and infliximab in order to correct renal ischemia-reperfusion injury.

Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD) are heterogeneous in their clinical presentation and underlying pathology, but they often have overlapping features. Diagnostic accuracy is critical for guiding patient management. Cerebrospinal fluid (CSF) diagnostic assays for the differentiation of AD and FTLD may increase diagnostic accuracy.In this study, we aimed to understand the potential role of CSF biomarkers and biomarker ratios, measured using Elecsys® CSF immunoassays (Roche Diagnostics International Ltd, Rotkreuz, Switzerland), in the differential diagnosis of AD and FTLD.This study was conducted at a single center in Munich, Germany between July 2019 and July 2020. Patient CSF samples were retrospectively collected from the study center biobank.A total of 130 patients with cognitive impairment were included in the study; 86 patients were diagnosed with AD and 44 with FTLD (behavioral variant frontotemporal dementia, semantic variant of primary progressive aphasia, and non-fluent variant of primary progressive aphasia), based on core clinical criteria and a non-CSF biomarker, a typical pattern of regional hypometabolism on [18F] fluorodeoxyglucose positron emission tomography.Patient CSF biomarker concentrations were measured using Elecsys CSF immunoassays. Receiver operating characteristic analyses were conducted to determine areas under the curve (AUCs) for CSF biomarker performance. Sensitivity and specificity analyses were conducted to evaluate the performance of established cut-offs (Aβ42 ≤1000 pg/mL, pTau181/Aβ42 ratio0.024, and tTau/Aβ42 ratio0.28) and optimized cut-offs based on Youden's index.AUC-based performance was similarly good for the pTau181/Aβ42 ratio (AUC=0.841; 95% CI: 0.759-0.923), pTau181/Aβ40 ratio (AUC=0.837; 95% CI: 0.754-0.919), Aβ42/Aβ40 ratio (AUC=0.829; 95% CI: 0.746-0.912), tTau/Aβ42 ratio (AUC=0.822; 95% CI: 0.736-0.908), pTau181/Aβ42/Aβ40 ratio (AUC=0.817; 95% CI: 0.734-0.901), and Aβ42 (AUC=0.812; 95% CI: 0.722-0.902). Performance was slightly lower for the tTau/Aβ42/Aβ40 ratio (AUC=0.799; 95% CI: 0.713-0.885), pTau181 alone (AUC=0.793; 95% CI: 0.707-0.880), tTau/Aβ40 ratio (AUC=0.751; 95% CI: 0.657-0.844), and tTau alone (AUC=0.706; 95% CI: 0.613-0.799). The highest qualitative performance was observed with the pTau181/Aβ42 ratio with an established cut-off value of0.024 and optimized cut-off value of0.022: sensitivity and specificity values were 0.892 and 0.773, respectively.Elecsys CSF immunoassays demonstrate good diagnostic accuracy in differentiating patients with AD from those with FTLD. These immunoassays have the potential to support clinical decision making, i.e. in diagnosing patients with FTLD by excluding patients with amyloid positivity, which is indicative of underlying AD.